Umbilical Cord Stem Cell Therapy for Hair Loss: Evidence, Risks and FDA Status

Umbilical cord-derived stem cell therapy is among the experimental regenerative treatments being promoted for hair loss. Some clinics and commercial suppliers advertise umbilical cord products as a source of powerful regenerative cells and growth factors capable of stimulating dormant follicles, reversing hair thinning and restoring hair growth without conventional medications or surgery.

The scientific interest in umbilical cord-derived cells is legitimate. Umbilical cord tissue contains cells with biological properties that have attracted considerable research interest, including mesenchymal stromal cells, commonly called MSCs. Laboratory and animal studies suggest that these cells and certain substances they release may influence inflammation, cellular signaling and biological processes involved in hair follicle activity. However, there is a substantial difference between experimental research involving carefully isolated, characterized and cultured cells and the commercial products being administered to patients under the general description of umbilical cord stem cell therapy.

As of October 2026, no umbilical cord-derived stem cell or tissue allograft product has received FDA approval for treating androgenetic alopecia or any other form of hair loss.

Furthermore, products marketed as umbilical cord stem cell injections do not necessarily contain living, functional stem cells. Some may consist primarily of processed tissue components, extracellular matrix material, growth factors or other biological substances. The human clinical evidence specifically supporting umbilical cord-derived allograft injections for hair restoration remains insufficient to establish reliable effectiveness, an appropriate dose, a standardized treatment protocol or long-term safety.

For consumers, the central issue is not whether umbilical cord-derived cells have potential applications in regenerative medicine. They do. The question is whether the particular product being offered contains what is claimed, has been adequately studied and is legally authorized for the proposed medical use.

What Is Umbilical Cord Allograft Stem Cell Therapy?

An allograft is tissue or cellular material obtained from one person and transferred to another person of the same species. In regenerative medicine, umbilical cord allograft products are derived from donated umbilical cord tissue or associated biological materials collected following childbirth.

These products may originate from different components of the umbilical cord, including Wharton’s jelly, the connective tissue surrounding the umbilical blood vessels. Umbilical cord tissue contains various cellular populations and structural components, including cells that can be isolated and expanded under laboratory conditions. Certain cultured cells may exhibit characteristics associated with mesenchymal stromal cells.

However, an umbilical cord tissue allograft is not automatically equivalent to an isolated, viable mesenchymal stromal cell preparation. The composition of a finished commercial product depends on how the source tissue was collected, processed, preserved, stored and prepared for administration.

A vial marketed as containing umbilical cord stem cells may not contain a therapeutically meaningful population of living cells. Even when viable cells are present, their identity, biological functionality and ability to produce a clinically meaningful effect must be established separately.

What Are Mesenchymal Stromal Cells?

Mesenchymal stromal cells are cells found in several tissues, including bone marrow, adipose tissue and umbilical cord tissue. Certain populations can be cultured under laboratory conditions and demonstrate specific cellular characteristics, including the ability to differentiate into selected tissue types under experimental conditions.

These cells have attracted research interest because of their interactions with surrounding tissues and their ability to release signaling molecules that may influence inflammation, immune responses and cellular activity. The term mesenchymal stem cell is frequently used in commercial marketing. However, mesenchymal stromal cell is often the more appropriate term when the self-renewal and differentiation capabilities expected of true stem cells have not been fully established for the particular cell population.

This distinction is particularly important when clinics suggest that injected umbilical cord cells will automatically transform into new hair follicles. There is no established human clinical evidence demonstrating that commercially administered umbilical cord-derived mesenchymal stromal cells reliably develop into fully functional new scalp hair follicles.

What Is Wharton’s Jelly?

Wharton’s jelly is a gelatinous connective tissue found within the umbilical cord. Its primary physiological function involves providing structural support and protection for the umbilical blood vessels during pregnancy.

Researchers have isolated and cultured mesenchymal stromal cells from Wharton’s jelly, making it a subject of considerable interest in regenerative medicine. However, there is an important distinction between isolating viable stromal cells from Wharton’s jelly under controlled laboratory conditions and administering a commercially processed Wharton’s jelly allograft.

Processing can substantially change the original tissue. Depending on the methods used, a finished preparation may contain extracellular matrix components, cellular remnants, soluble biological molecules or variable numbers of living cells. Some preparations may contain biologically active substances without containing a meaningful population of viable mesenchymal stromal cells.

The fact that Wharton’s jelly is a source from which mesenchymal stromal cells can be isolated does not establish that every Wharton’s jelly product contains viable, functional stem cells. Likewise, biological effects demonstrated using living laboratory-cultured cells cannot automatically be attributed to a preparation composed primarily of nonliving tissue components or soluble signaling molecules.

The finished product must be evaluated on its own characteristics rather than the properties of the original donor tissue.

Does Every Umbilical Cord Allograft Contain Living Stem Cells?

No. This is one of the most important misconceptions surrounding commercially marketed umbilical cord treatments.

Umbilical cord tissue may contain cells capable of being isolated and cultured, but their presence in the original donor tissue does not establish their presence or viability in the finished product. Processing, preservation, freezing, thawing and storage may affect cell survival and biological activity.

Some commercial preparations are acellular or contain primarily structural tissue components rather than living mesenchymal stromal cells. Others may contain cellular material without demonstrating that the cells remain viable, functional or present in quantities sufficient to produce a therapeutic effect.

There are several important distinctions. A living cell is not necessarily a mesenchymal stromal cell, and an appropriately identified mesenchymal stromal cell is not necessarily capable of producing clinically meaningful hair growth.

A viability test may establish that some cells remain alive following processing. It does not establish their identity, relevant biological activity, ability to survive after administration or effectiveness for treating androgenetic alopecia.

Claims involving millions of stem cells should therefore be supported by appropriate product-specific testing, including reliable cell identification, viability measurements and relevant functional characterization when living cells are claimed.

The number of cells advertised is not equivalent to a clinically effective dose.

Are Umbilical Cord Stem Cells Better Because They Come From Newborn Tissue?

Not necessarily.

Some companies promote umbilical cord-derived cells as superior because they originate from tissue collected at birth rather than from an older adult. This marketing often emphasizes youthful cells, greater regenerative capacity and the absence of age-related cellular changes.

There are legitimate scientific reasons to investigate how donor age influences cellular characteristics. Laboratory studies have found differences in proliferation, signaling and other biological properties among cells obtained from different tissues and donors.

However, favorable characteristics observed in young donor-derived cells do not establish that commercially administered umbilical cord products produce superior hair restoration outcomes.

The comparison becomes even less meaningful when the finished product has not demonstrated that it contains viable, appropriately characterized cells.

A preparation derived from newborn tissue may contain cellular remnants, extracellular matrix material or other biological substances rather than the living cells emphasized in promotional claims.

Even when viable cells are present, their younger origin does not prove that they will survive administration, influence scalp follicles or reverse androgenetic alopecia.

Younger cellular origin is not proof of greater clinical effectiveness.

How Might Umbilical Cord-Derived Cells Affect Hair Growth?

Hair follicles are complex structures regulated by interactions between epithelial cells, dermal papilla cells, signaling molecules, hormones and surrounding tissues. Experimental research suggests that mesenchymal stromal cells and substances they release may influence biological processes relevant to hair follicle growth.

These proposed mechanisms include modulation of inflammatory signaling, release of certain growth factors, effects on dermal papilla cell activity, support of vascular processes and changes in pathways associated with the hair growth cycle. Some laboratory investigations have examined signaling pathways such as Wnt/beta-catenin, which participate in follicular development and cycling.

Researchers are also studying whether extracellular vesicles and other cell-derived materials can reproduce some of the signaling effects associated with cultured stromal cells. These mechanisms are scientifically plausible and justify further investigation. However, most of the supporting evidence remains preclinical, and the biological activity of a carefully characterized laboratory preparation cannot automatically be attributed to a commercial allograft product.

Demonstrating cellular activity in a laboratory does not establish that an injected preparation will reach the necessary follicular structures, remain biologically active or produce meaningful hair growth in humans. The specific preparation, its composition and its demonstrated clinical effects are more important than the general biological potential of its source tissue.

What Does the Human Clinical Evidence Actually Show?

The human clinical evidence specifically supporting umbilical cord-derived allograft stem cell therapy for androgenetic alopecia is limited. Research into cell-based and cell-derived treatments for hair loss is considerably broader than research specifically involving commercially processed umbilical cord allografts.

A 2024 systematic review examining stem cell-derived approaches for androgenetic alopecia identified 12 randomized controlled trials involving a variety of cellular and acellular interventions. The investigated materials included preparations associated with adipose tissue, hair follicles, bone marrow, umbilical cord blood and other cellular sources. Some studies reported improvements in hair density and other growth measurements.

However, these were not 12 randomized trials of umbilical cord tissue allograft injections. The review combined biologically different interventions, including preparations obtained from a patient’s own tissue and treatments involving cell-derived substances rather than living donor stem cells.

Although the review’s authors characterized the overall findings favorably, the diversity of treatments, relatively small studies and limitations in follow-up make it inappropriate to conclude that every category of stem cell-derived therapy has established safety and effectiveness.

A broader 2026 systematic review examined 20 clinical studies involving 724 patients across several regenerative approaches, including conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles and stem cell-related treatments.

Although the review described encouraging outcomes for selected interventions, those findings do not establish a standardized, clinically validated umbilical cord allograft injection protocol for androgenetic alopecia. The aggregate number of patients across different regenerative treatment categories should not be mistaken for the number of patients studied using the specific allograft preparations being commercially promoted.

The appropriate conclusion is that cell-based and cell-derived regenerative medicine has demonstrated biological and early clinical potential. However, the evidence remains insufficient to establish that commercially marketed umbilical cord-derived tissue allograft injections provide reliable, clinically meaningful or durable hair restoration.

Why Can’t Results From Other Stem Cell Studies Be Applied to Umbilical Cord Allografts?

The term stem cell therapy is used to describe numerous biologically different interventions. Some studies use cells obtained from the patient’s own adipose tissue. Others investigate cultured cells, cell-conditioned media, extracellular vesicles, cellular micrografts or donor-derived biological preparations.

These interventions can differ substantially in their cellular composition, manufacturing methods, biological activity and potential risks. An autologous preparation, obtained from the patient receiving treatment, is not equivalent to an allogeneic preparation derived from another individual.

Likewise, a laboratory-expanded culture of viable mesenchymal stromal cells is not necessarily comparable to a frozen and thawed tissue allograft prepared for direct injection. The fact that these treatments are discussed together in systematic reviews does not make them interchangeable.

A positive study involving adipose-derived cellular material cannot establish the effectiveness of a Wharton’s jelly allograft. Similarly, research involving extracellular vesicles released by cultured umbilical cord cells does not establish that a commercial umbilical cord tissue preparation contains the same material or produces the same clinical effect.

This distinction is particularly important when clinics cite regenerative medicine research without demonstrating that the studies involved the actual product being offered. Clinical evidence must be relevant to the preparation, route of administration and medical condition being treated.

Can Umbilical Cord Stem Cells Create New Hair Follicles?

There is no established clinical evidence that commercially administered umbilical cord-derived allograft products can reliably create entirely new, fully functional human scalp follicles.

Experimental studies have explored the ability of certain cells and signaling molecules to influence follicular development and hair growth. However, influencing the activity of existing follicles is fundamentally different from generating a new follicular organ.

In androgenetic alopecia, follicles progressively miniaturize as a result of genetic and hormonal susceptibility. Some miniaturized follicles may retain biological activity that can be influenced by treatment. Completely destroyed follicles, particularly those lost through scarring disorders, present a different challenge.

Claims that umbilical cord stem cell injections can reliably regenerate completely bald scalp, reverse permanent follicular destruction or replace hair transplantation are not supported by established human clinical evidence.

Can Umbilical Cord Stem Cells Stop DHT-Related Hair Loss?

There is no convincing clinical evidence that umbilical cord-derived allograft injections eliminate the underlying hormonal and genetic processes responsible for androgenetic alopecia.

Male and female pattern hair loss involve progressive changes in susceptible follicles, with androgen signaling playing an important role. Although experimental cellular therapies may influence certain pathways involved in follicular activity, this does not establish that they provide sustained control of androgenetic alopecia.

Umbilical cord allograft products have not been demonstrated to replace finasteride, dutasteride, minoxidil or other evidence-supported therapies. Even if a particular experimental preparation eventually demonstrates improvements in hair density, long-term studies would be necessary to determine whether those benefits persist while the underlying condition continues.

A temporary increase in hair growth measurements should not be confused with permanent disease stabilization.

Are Umbilical Cord Stem Cell Treatments the Same as Exosome Therapy?

No. Umbilical cord-derived mesenchymal stromal cell therapy involves cellular preparations containing living cells when such cells are actually present and viable. Exosome-based approaches involve extracellular vesicles and associated molecular components rather than living cells.

Researchers may obtain extracellular vesicles from cultured umbilical cord-derived cells, but the resulting extracellular vesicle preparation is a different biological product from the original cells. Similarly, conditioned media and secretome preparations may contain proteins, growth factors and extracellular vesicles released by cultured cells.

These substances should not be described as equivalent to living stem cells. A product containing nonliving growth factors or extracellular matrix components may possess certain biological properties, but it cannot automatically be credited with the ongoing cellular functions of living mesenchymal stromal cells.

Evidence involving umbilical cord-derived extracellular vesicles does not automatically establish the effectiveness of umbilical cord tissue injections, and research involving cultured cells does not validate every cell-derived commercial product.

Are Umbilical Cord Allografts More Effective Than PRP?

There is insufficient high-quality evidence to conclude that umbilical cord allograft treatments are more effective than platelet-rich plasma for androgenetic alopecia.

PRP has a considerably larger body of randomized human clinical research supporting potential improvements in hair density for appropriately selected patients. Although PRP preparations remain incompletely standardized, PRP is derived from the patient’s own blood and does not involve the same donor tissue sourcing and cellular product manufacturing issues associated with umbilical cord allografts.

Umbilical cord-derived products introduce additional uncertainties involving product identity, cell viability, donor screening, processing, storage and regulatory authorization. Some clinics describe umbilical cord stem cell therapy as more powerful, more advanced or more regenerative than PRP.

Those claims are not established by comparative clinical evidence. There is no justification for assuming that a treatment is superior simply because its biological source is different, because the donor tissue was collected at birth or because it is marketed as a more advanced regenerative technology.

Is Umbilical Cord Stem Cell Therapy FDA Approved for Hair Loss?

No. There are no FDA-approved umbilical cord tissue allograft stem cell products for treating androgenetic alopecia or other forms of hair loss.

The FDA has approved certain umbilical cord blood-derived hematopoietic stem and progenitor cell products for specified disorders involving the blood-forming system. These products have established medical applications in appropriate patients, but they are not approved for hair restoration.

Umbilical cord blood transplantation and commercially marketed umbilical cord tissue injections are fundamentally different applications. FDA approval of a cord blood-derived hematopoietic cell product does not establish the safety or effectiveness of an unrelated Wharton’s jelly preparation or umbilical cord-derived mesenchymal stromal cell injection.

Consumers should not accept the statement that umbilical cord stem cells are FDA approved without determining exactly which product and medical indication are being discussed.

What Does Minimal Manipulation Mean?

Minimal manipulation is an important concept in FDA regulation of human cells, tissues and cellular or tissue-based products, commonly called HCT/Ps.

Under certain circumstances, qualifying HCT/Ps may be regulated solely under Section 361 of the Public Health Service Act and its associated regulations rather than requiring premarket approval as biological drugs.

However, this regulatory pathway is subject to specific requirements. Under 21 CFR 1271.10(a), a product generally must satisfy all four applicable criteria:

  • The cells or tissue must be minimally manipulated.
  • The product must be intended for homologous use only.
  • Manufacturing must satisfy restrictions concerning combination with other articles.
  • The product must satisfy requirements related to systemic effects and dependence on the metabolic activity of living cells, including restrictions applicable to certain allogeneic uses.

Satisfying only one of these requirements does not establish that a product qualifies for regulation solely under Section 361.

The fourth criterion is particularly relevant to products marketed as containing living donor-derived stem cells. When a product has a systemic effect or depends on the metabolic activity of living cells for its primary function, the applicable regulatory exception generally requires autologous use, use in certain close blood relatives or reproductive use.

An unrelated donor-derived cellular product cannot automatically qualify simply because it originates from umbilical cord tissue or because the manufacturer describes its processing as minimal.

For structural tissues such as umbilical cord tissue, minimal manipulation is assessed in relation to characteristics relevant to the tissue’s original utility for reconstruction, repair or replacement. Processing that alters those characteristics may affect regulatory classification.

The FDA has addressed these issues in guidance and enforcement actions involving umbilical cord-derived products. Consumers should be cautious when manufacturers use the term minimally manipulated as though it independently establishes legal authorization for treating hair loss.

What Is Homologous Use, and Why Does It Matter?

Homologous use generally means that human cells or tissues are intended to perform the same basic function in the recipient that they performed in the donor.

Umbilical cord tissue and umbilical cord blood have different basic biological functions. Umbilical cord tissue serves important structural functions associated with protecting and supporting the umbilical vessels and maintaining the conduit between the fetus and placenta. Cord blood, by contrast, contains hematopoietic stem and progenitor cells associated with the blood-forming system.

Injecting processed umbilical cord tissue into an adult scalp for the purpose of stimulating hair growth is not equivalent to using that tissue for its original basic structural function.

Likewise, the established use of cord blood-derived hematopoietic cells for certain blood disorders does not support using unrelated umbilical cord products to stimulate scalp follicles.

Consequently, a manufacturer’s assertion that its product qualifies for a regulatory pathway based on homologous use requires careful scrutiny. The FDA has issued warning letters addressing umbilical cord-derived products promoted for applications that differ from the tissue’s original basic functions.

These regulatory distinctions are not merely technical. They affect the requirements for manufacturing, clinical investigation and authorization to market a biological product.

Does FDA Registration Make Umbilical Cord Stem Cell Therapy Legal?

No. A manufacturing establishment may be registered with the FDA without having an FDA-approved product. Similarly, tissue-bank registration, laboratory certification or compliance with certain manufacturing requirements does not necessarily establish that a product is legally authorized for treating hair loss.

A clinic may advertise a preparation as FDA registered, ethically donated, laboratory tested or produced in a regulated facility. These claims do not demonstrate that the finished product has been approved for the proposed medical use.

Recent FDA enforcement actions provide concrete examples of the regulatory concerns surrounding commercially marketed umbilical cord-derived products.

In February 2026, the FDA issued a warning letter to Dynamic Stem Cell Therapy involving an umbilical cord-derived cellular product that the agency identified as an unapproved drug and unlicensed biological product.

In August 2026, the FDA issued a warning letter to R3 Medical Companies concerning umbilical cord-related and extracellular vesicle products. The agency identified regulatory concerns involving product classification and marketing, as well as deficiencies associated with manufacturing controls and contamination prevention.

These actions demonstrate that the issues are not theoretical. They involve products actually being promoted or distributed for therapeutic applications.

However, enforcement findings involving particular companies should not be interpreted as establishing that every manufacturer has committed identical violations.

The broader lesson is that consumers must distinguish the regulatory status of a manufacturer or tissue establishment from the legal marketing status of the specific product being administered.

FDA registration is not FDA approval. A tissue-bank license is not proof of hair-growth effectiveness.

What If a Clinic Offers Umbilical Cord Stem Cell Therapy Outside the United States?

Regulatory requirements for cellular and tissue-derived treatments vary internationally.

A product may be commercially available or authorized for a particular use in another country without having FDA approval in the United States.

Likewise, the fact that a physician or clinic routinely administers an umbilical cord-derived preparation in another jurisdiction does not establish that the treatment has demonstrated effectiveness for androgenetic alopecia.

Consumers should distinguish legitimate authorization for a defined product and medical indication from broad claims that a country permits stem cell therapy.

Different countries may apply different standards to manufacturing, clinical evidence, practitioner oversight and the administration of experimental biological products.

International availability should not be confused with scientific validation.

Patients considering treatment abroad should understand the precise regulatory status of the product, the evidence supporting the proposed indication, manufacturing oversight, complication management and arrangements for medical follow-up after returning home.

Can Umbilical Cord Stem Cell Treatments Be Studied in Clinical Trials?

Yes. Umbilical cord-derived cells and related biological preparations can be investigated through properly designed clinical research.

Depending on the product and proposed application, an Investigational New Drug application, commonly called an IND, may be required before human clinical studies can proceed. An IND permits certain investigational treatments to be evaluated under applicable FDA oversight. It does not mean the product has been approved as safe or effective.

For example, a clinical trial protocol published in 2026 described a planned randomized investigation of small extracellular vesicles derived from human umbilical cord mesenchymal stromal cells in young men with androgenetic alopecia.

This is scientifically relevant research, but it concerns extracellular vesicles rather than administration of a commercially available umbilical cord tissue allograft. Furthermore, publication of a study protocol does not establish that the treatment has demonstrated clinical effectiveness.

Patients considering investigational treatment should understand the applicable regulatory authorization, independent ethical oversight, study objectives and safety-monitoring procedures. A clinical trial registration number by itself does not establish that a product has received FDA approval or that a commercial treatment is authorized.

Are Umbilical Cord Allograft Injections Safe?

The safety of commercially marketed umbilical cord allograft injections for hair loss has not been adequately established. Safety concerns depend on the exact product, its composition, processing, donor source, manufacturing controls and method of administration.

Potential risks include:

  • Bacterial, viral or other biological contamination
  • Local or systemic infection
  • Inflammatory or immune reactions
  • Injection-related bleeding, pain or tissue injury
  • Inconsistent cellular content or cell viability
  • Unwanted biological activity from poorly characterized preparations
  • Manufacturing or storage failures
  • Unknown effects following repeated administration
  • Delayed diagnosis or treatment of the underlying hair loss condition

It is important to distinguish documented complications from potential or theoretical risks.

Serious infections have occurred following administration of particular contaminated donor-derived regenerative products. Other concerns, including unwanted cellular activity and delayed biological effects, depend heavily on the nature of the preparation and have not been adequately evaluated in patients receiving umbilical cord allograft scalp injections.

These concerns do not establish that every umbilical cord-derived preparation will cause complications. They demonstrate why careful product characterization, clinical testing and appropriate regulatory oversight are necessary.

The FDA has warned that unapproved regenerative medicine products may expose patients to serious health risks. The fact that a biological product originates from donated tissue collected after childbirth does not make it inherently safe.

Have Serious Infections Occurred With Umbilical Cord-Derived Products?

Yes. The Centers for Disease Control and Prevention documented serious bacterial infections associated with specific contaminated umbilical cord blood-derived products administered for unapproved indications.

In a 2018 investigation, 12 patients across three states developed infections following administration of products distributed for uses unrelated to hematopoietic or immunologic reconstitution. The infections included bloodstream infections, joint infections and an epidural abscess, and all 12 patients required hospitalization. Testing identified bacterial contamination in unopened product containers.

These events did not involve treatment for hair loss and should not be presented as evidence that scalp injections of every umbilical cord-derived product carry the same risk.

However, they demonstrate that serious complications can occur when donor-derived biological products are inadequately controlled for contamination.

Patients should not assume that a frozen vial containing human tissue-derived material is sterile or safe simply because a clinic describes it as medically prepared.

Can Donor-Derived Cells Cause Immune Reactions?

Potentially. Allogeneic products originate from another individual, introducing considerations involving biological compatibility and immune responses.

Mesenchymal stromal cells have attracted research interest partly because of their potential immunomodulatory characteristics. However, this does not mean that every donor-derived cellular preparation is immunologically invisible or incapable of producing inflammatory reactions.

The potential for immune responses depends on the actual product, viable cell content, donor characteristics, processing and administration method. Commercial claims that umbilical cord-derived cells are completely immune privileged or cannot cause rejection should be treated cautiously.

There is insufficient long-term clinical evidence to establish the frequency or severity of immune complications associated with commercially marketed umbilical cord allograft scalp injections.

Can Umbilical Cord Stem Cells Cause Tumors or Unwanted Tissue Growth?

There is no established clinical evidence that commercially marketed umbilical cord allograft injections for hair loss routinely cause tumors.

However, long-term safety has not been adequately evaluated, and cellular therapies can present biological considerations involving cell proliferation, differentiation and unintended tissue responses. These risks depend on the particular cell population, degree of manipulation, manufacturing methods and administration route.

Importantly, different classes of cellular therapy do not have identical biological risks. Research involving carefully characterized mesenchymal stromal cells should not be treated as equivalent to research involving pluripotent stem cells or poorly characterized commercial tissue allografts.

The FDA has identified tumor formation and unwanted tissue growth among potential concerns associated with certain unapproved regenerative medicine interventions. This should not be interpreted as proof that umbilical cord scalp injections cause cancer.

The scientifically defensible conclusion is that comprehensive long-term safety has not been established for these commercially marketed hair-loss treatments.

What About Pregnancy, Breastfeeding and Younger Patients?

There is insufficient evidence establishing the safety or effectiveness of umbilical cord-derived allograft injections for hair loss during pregnancy or breastfeeding. There are also no validated protocols supporting routine commercial use in children or adolescents with hair loss.

Because these interventions remain experimental, elective treatment during pregnancy or breastfeeding is not advisable. Children and adolescents with hair loss require careful diagnosis and age-appropriate medical evaluation rather than exposure to commercially marketed regenerative procedures lacking adequate clinical evidence.

The absence of documented complications in a particular population should not be confused with established safety.

Does Donor Screening Guarantee Product Safety?

No. Appropriate donor eligibility evaluation and infectious disease screening are important components of manufacturing certain human cell and tissue products.

However, donor screening alone does not establish that a finished product is sterile, contains viable cells, has consistent biological activity or is clinically effective. Contamination can occur during collection, processing, packaging, storage or administration.

In addition, donor screening does not address every risk associated with cellular identity, potency, immune responses or long-term biological effects. A product may come from a carefully screened donor and still lack adequate clinical evidence supporting its proposed use for hair restoration.

Product traceability, manufacturing quality controls and appropriate testing are important, but none of these independently establishes clinical effectiveness.

Does Freezing and Thawing Affect Stem Cell Viability?

It can. Cryopreservation is widely used in legitimate cellular research and medical applications, but successful preservation requires appropriate methods, validated procedures and quality control.

Cell survival after thawing depends on the cellular material, preservation solution, freezing protocol, storage conditions and thawing process. Some cells may remain viable after appropriately controlled cryopreservation, while others may be damaged or lose aspects of their biological functionality.

A manufacturer should not assume that a frozen umbilical cord preparation contains viable, functional stem cells simply because the original donor tissue contained cells capable of being cultured.

Similarly, demonstrating that some cells survive thawing does not prove that they retain the biological properties needed for a proposed therapeutic effect. Post-thaw viability is only one quality characteristic and does not establish cellular identity, potency or clinical effectiveness.

There is no established evidence that commercially marketed frozen and thawed umbilical cord tissue injections provide a reliable dose of functional hair-regenerating cells.

Are Higher Stem Cell Counts Better?

That has not been established for hair restoration. Some companies advertise products containing millions of stem cells or particularly high concentrations of cellular material.

However, the claimed number may not distinguish between living cells, nonviable cells and other cellular components. Even when a viable cell count is accurately established, it does not demonstrate that the cells are appropriately characterized, possess relevant biological activity or produce meaningful hair growth.

There is no validated dose-response relationship for umbilical cord-derived allograft cell injections in androgenetic alopecia.

A higher advertised cell count is not proof of superior effectiveness. Likewise, larger injection volumes and more frequent treatments have not been shown to provide predictable additional benefit.

How Many Treatments Are Needed?

There is no standardized, clinically validated treatment schedule for umbilical cord-derived allograft injections for androgenetic alopecia. Commercial recommendations may involve one treatment or a series of procedures, but those schedules should not be mistaken for established medical protocols.

The appropriate cellular dose, administration method, treatment interval and need for maintenance remain undetermined. There is also insufficient evidence to determine how long any potential benefit would persist.

Patients should be cautious about purchasing repeated treatments based on assurances that additional injections will produce stronger or more durable results. More treatments do not automatically mean greater effectiveness, especially when an effective initial treatment protocol has not been established.

Can Umbilical Cord Stem Cell Therapy Treat Alopecia Areata or Scarring Alopecia?

There is insufficient clinical evidence to recommend commercially marketed umbilical cord-derived allograft treatments for alopecia areata or scarring alopecia.

Alopecia areata is an autoimmune condition, while scarring alopecias involve inflammatory processes that can permanently destroy follicles. Laboratory findings suggesting that mesenchymal stromal cells possess immunomodulatory properties do not establish that injecting donor-derived preparations into the scalp will control these diseases.

Patients with active scarring alopecia require timely diagnosis and disease-directed management. Delaying appropriate treatment while pursuing experimental regenerative procedures may allow additional irreversible follicular destruction.

The AHLA does not consider umbilical cord allograft therapy an established substitute for evidence-supported treatment of these conditions.

How Much Should Umbilical Cord Stem Cell Therapy Cost?

There is no scientifically established price or cost-effectiveness benchmark for umbilical cord-derived allograft therapy for hair loss.

Prices may vary according to the clinic, supplier, preparation and proposed treatment protocol. However, high prices do not establish that a product contains living stem cells or that it is clinically effective.

Patients should understand exactly what they are purchasing, including the biological source, actual product composition, proposed number of treatments and available clinical evidence. A proprietary preparation, large advertised cell count or sophisticated laboratory terminology should not be used as a substitute for published product-specific clinical research.

The AHLA is particularly concerned about expensive prepaid packages involving treatments that have not been demonstrated to be safe and effective for androgenetic alopecia. Financial commitments should not be based on promises of cellular regeneration or permanent hair restoration that have not been substantiated.

What Should Consumers Ask Before Considering Umbilical Cord Stem Cell Therapy?

Consumers should ask specific questions rather than relying on general descriptions of regenerative medicine.

Important questions include:

  • What exact product is being administered?
  • Is the product derived from umbilical cord tissue, cord blood or Wharton’s jelly?
  • Does the finished preparation contain living cells?
  • If living cells are claimed, how are their identity and viability established?
  • What is the actual viable cell count following preparation or thawing?
  • What evidence demonstrates that the cells retain relevant biological functionality?
  • Is the product an intact tissue allograft, processed tissue preparation, isolated cell product or cell-derived material?
  • What donor screening and manufacturing controls are used?
  • Has the finished product been evaluated in published human clinical trials specifically for androgenetic alopecia?
  • Is the product FDA approved for the proposed use?
  • If it is investigational, what regulatory authorization applies?
  • What evidence supports the proposed injection dose and treatment schedule?
  • What adverse events have been reported?
  • What is known about long-term safety?
  • How will treatment response be measured objectively?
  • What is the total financial commitment?
  • What happens if the treatment produces no measurable benefit?

A physician should be able to distinguish the characteristics of the actual product from the general properties of cells found in umbilical cord tissue. Consumers should be particularly cautious when a provider cannot clearly identify the preparation, offers no product-specific clinical evidence or suggests that FDA registration alone establishes authorization to administer the treatment.

The AHLA Perspective

Umbilical cord-derived cells and their associated biological products represent an important area of regenerative medicine research. Their potential effects on inflammation, cellular signaling and tissue responses provide legitimate reasons for continued scientific investigation.

However, the American Hair Loss Association is concerned about the commercialization of umbilical cord-derived allograft treatments before adequate evidence has established their clinical value for hair restoration.

One of the central problems is the frequent failure to distinguish between living, laboratory-characterized mesenchymal stromal cells and commercially processed umbilical cord tissue products. The fact that researchers can isolate viable cells from Wharton’s jelly does not establish that an injected commercial preparation contains those cells. Nor does it demonstrate that the product can regenerate hair follicles, reverse androgenetic alopecia or provide benefits beyond established treatment.

Likewise, findings involving adipose-derived cells, conditioned media, extracellular vesicles or other regenerative preparations cannot automatically be applied to umbilical cord allografts. A review identifying promising results across different cellular therapies does not establish clinical effectiveness for an unrelated commercial tissue preparation.

The source of a biological product does not establish its effectiveness. Its cellular composition, viability, biological functionality and clinical performance must be demonstrated rather than assumed.

FDA regulatory concerns are also substantial. Products marketed for hair restoration may require approval as drugs or biological products, and registration of a tissue establishment does not establish that a treatment is legally authorized for this use. Recent FDA enforcement actions involving umbilical cord-related products reinforce the importance of product-specific regulatory scrutiny and appropriate manufacturing controls.

The AHLA recognizes that advances in cell-based medicine may eventually produce meaningful new treatments for hair loss. Properly conducted clinical research involving characterized cells, defined manufacturing standards, appropriate regulatory oversight and objective clinical outcomes should be encouraged.

At present, however, the AHLA does not recommend commercially marketed umbilical cord-derived stem cell or tissue allograft injections for hair loss outside appropriately regulated clinical research.

This position reflects the limitations of current clinical evidence, uncertainties concerning product composition and cell viability, unresolved treatment protocols, inadequate long-term safety data and important regulatory considerations.

Consumers should not be persuaded by the term stem cell alone. Nor should they assume that material derived from tissue collected at childbirth is inherently safe, biologically superior or capable of unlimited regeneration.

A treatment should be judged by what the finished product actually contains, what high-quality clinical research demonstrates and whether its potential benefits justify its risks.

The ability to obtain stem cells from umbilical cord tissue is established science. The claim that commercially marketed umbilical cord allograft injections reliably restore human scalp hair is not.

Selected References

1. U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA

2. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. FDA

3. U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular or Tissue-Based Products: Minimal Manipulation and Homologous Use. Guidance for Industry. FDA

4. Electronic Code of Federal Regulations. 21 CFR 1271.10. Criteria for Regulation of Human Cells, Tissues, and Cellular or Tissue-Based Products Solely Under Section 361 of the Public Health Service Act. eCFR

5. Gasteratos K, Kouzounis K, Goverman J. Autologous Stem Cell-derived Therapies for Androgenetic Alopecia: A Systematic Review of Randomized Control Trials on Efficacy, Safety, and Outcomes. Plast Reconstr Surg Glob Open. 2024;12:e5606. PubMed

6. A Systematic Review of Clinical Evidence on the Efficacy and Safety of Conditioned Media, Platelet-Rich Fibrin, Stromal Vascular Fraction, Extracellular Vesicles, and Stem Cells in Androgenetic Alopecia. 2026. PubMed

7. Tian R, et al. A Randomized Controlled Clinical Trial Protocol of Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles for the Treatment of Androgenetic Alopecia in Young Males. FASEB J. 2026. Original Journal

8. Perkins KM, et al. Notes from the Field: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood-Derived Stem Cell Products for Other Than Hematopoietic or Immunologic Reconstitution, United States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67:1397–1399. CDC

9. U.S. Food and Drug Administration. Warning Letter to Dynamic Stem Cell Therapy. February 11, 2026. FDA

10. U.S. Food and Drug Administration. Warning Letter to R3 Medical Companies. August 14, 2026. FDA

Education - 

Research - 

Commitment